LifeSci Capital Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $45

Futu News10:32 · Ratings

Buy Recommendation for Dianthus Therapeutics: Strong Financial Position and Promising Drug Pipeline

TipRanks09:45

Dianthus Therapeutics Q3 2024 GAAP EPS $(0.74) Misses $(0.58) Estimate, Sales $2.17M Beat $648.50K Estimate

Benzinga06:00

Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates

Zacks 05:50

Dianthus Therapeutics | 10-Q: Quarterly report

SEC05:10 · Announcements

Express News | Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

Breakings05:01